Last reviewed · How we verify

fluticasone propionate + montelukast — Competitive Intelligence Brief

fluticasone propionate + montelukast (fluticasone propionate + montelukast) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid + Leukotriene receptor antagonist. Area: Respiratory.

phase 3 Corticosteroid + Leukotriene receptor antagonist Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

fluticasone propionate + montelukast (fluticasone propionate + montelukast) — Milton S. Hershey Medical Center. Fluticasone propionate is a corticosteroid that reduces inflammation, while montelukast is a leukotriene receptor antagonist that prevents bronchospasm.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
fluticasone propionate + montelukast TARGET fluticasone propionate + montelukast Milton S. Hershey Medical Center phase 3 Corticosteroid + Leukotriene receptor antagonist

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid + Leukotriene receptor antagonist class)

  1. Milton S. Hershey Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). fluticasone propionate + montelukast — Competitive Intelligence Brief. https://druglandscape.com/ci/fluticasone-propionate-montelukast. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: